Incidence of viral hepatitis after administration of factor IX concentrates.

Abstract

A high frequency of viral hepatitis has been reported after treatment with the human factor IX concentrate 'Konyne'. Clinical trials with 'Konyne' and a similar factor IX concentrate, called 'Preconativ', was started in Sweden 1969. During the first 2 years, 26 patients were treated with either one or both preparations. Nine patients developed viral hepatitis within 6 months after treatment. 'Preconativ' alone was introduced on the Swedish market in 1971. During the period 1971-1974, another 26 hemophiliacs were treated but only two cases of hepatitis have occurred. Selection of donors and screening for hepatitis B surface antigen in donor blood used for the manufacturing of 'Preconativ', might be contributing factors to this low hepatitis incidence.

• Authors: S Iwarson, H Kjellman, A C Teger-Nilsson
• Journal: Vox sanguinis (Vox Sang) Vol. 31 Issue 2 Pg. 136-40 ( 1976) ISSN: 0042-9007 [Print] England
• PMID: 951972 (Publication Type: Journal Article)

Chemical References

• Factor IX

Topics

• Factor IX (adverse effects)
• Hepatitis A (etiology, immunology)
• Humans
• Sweden
• Transfusion Reaction